- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06596772
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients With Moderate to Severe Rheumatoid Arthritis
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study will randomize approximately 458 patients aged between 18 and 75 years with active Rheumatoid Arthritis despite methotrexate therapy.
All patients shall receive methotrexate for ≥12 weeks and on a stable dose (10 to 25 mg/week) for ≥8 weeks prior to randomization, and folic acid (≥5 mg/week) from 4 weeks prior to screening until the end of the treatment period (Week 36).
Screening evaluations will be completed within 28 days prior to randomization. There will be 2 periods in the study: Main Treatment Period and Transition Period.
During the Main Treatment Period, eligible patients will be randomized, at a 1:1 ratio, to administer a 50 mg weekly dose of MB04 or EU- sourced Enbrel® subcutaneously (SC) using an Interactive Response System (IRT). After completing Week 24 assessment, patients will continue to receive the study treatment up to Week 36. Those patients who were originally assigned to EU-sourced Enbrel® will be randomized, at a 1:1 ratio, to receive either MB04 or EU-sourced Enbrel® SC, while patients originally assigned to MB04 will continue with the same treatment until Week 36.
After treatment discontinuation, patients will undergo a Safety Follow-up Period for 4 weeks, up to Week 40.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Haskovo, Bulgarien
- Research site 2007
-
Plovdiv, Bulgarien
- Research site 2005
-
Rousse, Bulgarien
- Research Site 2002
-
Sofia, Bulgarien
- Research site 2001
-
Sofia, Bulgarien
- Research Site 2003
-
Sofia, Bulgarien
- Research Site 2008
-
Vidin, Bulgarien
- Research site 2004
-
Vratsa, Bulgarien
- Research site 2006
-
-
-
-
-
Batumi, Georgien
- Research site 7004
-
Batumi, Georgien
- Research site 7010
-
Tbilisi, Georgien
- Research site 7001
-
Tbilisi, Georgien
- Research site 7002
-
Tbilisi, Georgien
- Research site 7003
-
Tbilisi, Georgien
- Research site 7005
-
Tbilisi, Georgien
- Research site 7006
-
Tbilisi, Georgien
- Research site 7007
-
Tbilisi, Georgien
- Research site 7009
-
-
-
-
-
Chisinau, Mögel, MD-2068
- Research Site 1301
-
Chisinau, Mögel, MD2025
- Research site 1302
-
Chisinau, Mögel
- Research site 1303
-
-
-
-
-
Bialystok, Polen
- Research Site 1603
-
Bialystok, Polen
- Research Site 1614
-
Bialystok, Polen
- Research site 1616
-
Bydgoszcz, Polen
- Research site 1613
-
Bytom, Polen
- Research site 1623
-
Elblag, Polen
- Research Site 1615
-
Elblag, Polen
- Research Site 1627
-
Gdynia, Polen
- Research Site 1606
-
Katowice, Polen
- Research Site 1611
-
Krakow, Polen
- Research Site 1617
-
Lublin, Polen
- Research Site 1622
-
Nowa Sól, Polen
- Research site 1605
-
Opole, Polen
- Research Site 1618
-
Piotrkow Trybunalski, Polen
- Research site 1628
-
Poniatowa, Polen
- Research Site 1624
-
Poznan, Polen
- Research Site 1601
-
Poznan, Polen
- Research Site 1602
-
Poznan, Polen
- Research Site 1608
-
Poznan, Polen
- Research Site 1619
-
Poznan, Polen
- Research Site 1621
-
Siedlce, Polen
- Research Site 1612
-
Sochaczew, Polen
- Research Site 1610
-
Stalowa Wola, Polen
- Research site 1629
-
Torun, Polen
- Research Site 1620
-
Warsaw, Polen
- Research Site 1604
-
Warsaw, Polen
- Research Site 1607
-
Warsaw, Polen
- Research Site 1609
-
Wroclaw, Polen
- Research Site 1625
-
Zamość, Polen
- Research Site 1626
-
-
-
-
-
Bacau, Rumänien
- Research Site 1803
-
Brasov, Rumänien
- Research Site 1805
-
Bucharest, Rumänien
- Research Site 1801
-
Bucharest, Rumänien
- Research site 1802
-
Bucharest, Rumänien
- Research site 1804
-
Râmnicu Vâlcea, Rumänien
- Research site 1806
-
-
-
-
-
Belgrade, Serbien
- Research site 1903
-
Belgrade, Serbien
- Research site 1904
-
Belgrade, Serbien
- Research site 1905
-
Novi Sad, Serbien
- Research Site 1902
-
Zrenjanin, Serbien
- Research site 1901
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion
- Documented history of RA diagnosis consistent with the 2010 ACR/EULAR classification criteria ≥6 months prior to randomization (but not exceeding 15 years prior to screening).
- Moderately to severe RA despite appropriate MTX at baseline therapy defined as having more than or equal to six swollen joints and more than or equal to six tender joints and either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive protein > 5.0 mg/dL and positive rheumatoid factor and/or CCP at screening
- Stable dose MTX between 10 to 25 mg weekly during ≥12 weeks, since ≥8 weeks prior to randomization
- Stable dose of NSAID and/or other analgesics for at least 4 weeks prior to randomization, when used
- Stable dose ≤10 mg prednisone daily or equivalent for ≥4 weeks prior to randomization, when used
- Patients who are otherwise medically stable according to investigator's discretion
- Agree to use highly effective contraceptive methods up to 6 months after last dose Exclusion
- Previously treated with any biologic or targeted synthetic DMARD
- Previously treated with any monoclonal antibody for a condition other than RA
- Hypersensitivity to any component of study drug and/or prefilled syringe components
- Arthritis with onset prior to age 16 years or current diagnosis of inflammatory joint disease other than RA
- Systemic manifestations of RA other than rheumatoid nodules or secondary Sjogren's syndrome
- Active infection or potentially relapsing infections that could have a severe outcome. Latent tuberculosis infection detected during screening should start an approved treatment regimen according to standard of care and rescreened
- Solid or hematologic malignancy within the past 5 years
- Pregnant and breastfeeding women
- Any medical condition in the opinion of the investigator that would be a risk for safety, cooperation in the study or interferes with the interpretation of the study results
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: MB04 (proposed etanercept biosimilar)
MB04 50 mg/week via subcutaneous injection |
MB04 50 mg/week via subcutaneous injection |
|
Aktiv komparator: Enbrel (etanercept)
Enbrel 50 mg/week via subcutaneous injection |
Enbrel 50 mg/week via subcutaneous injection |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
American College of Rheumatology 20 % svarskriterier (ACR20)
Tidsram: Vecka 24
|
Vecka 24
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
ACR20
Tidsram: Vecka 36
|
Vecka 36
|
|
American College of Rheumatology 50 % svarskriterier (ACR50)
Tidsram: Vecka 24 och 36
|
Vecka 24 och 36
|
|
American College of Rheumatology 70 % svarskriterier (ACR70)
Tidsram: Vecka 24 och 36
|
Vecka 24 och 36
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Muskuloskeletala sjukdomar
- Artrit
- Ledsjukdomar
- Reumatiska sjukdomar
- Bindvävssjukdomar
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Hud- och bindvävssjukdomar
- Artrit, reumatoid
- Peptider
- Aminosyror, peptider och proteiner
- Proteiner
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Receptorer, cellytan
- Membranproteiner
- Immunoglobulin FC -fragment
- Immunoglobulinfragment
- Peptidfragment
- Immunoglobulinkonstantregioner
- Receptorer, tumörnekrosfaktor
- Receptorer, cytokin
- Receptorer, immunologiska
- Etanercept
Andra studie-ID-nummer
- MB04-C-01-23
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .